The peptide does not need to be injected into or near the shoulder joint itself
Gregory Frontiers in Medicine doi 10.3389/fmed.2021.670643 6,009 views 8 citations Mini Review Published on 24 Mar 2021 Implementation of Pharmacogenomic Information on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Ophthalmology Eri Tsukagoshi Yoichi Tanaka Yoshiro Saito Frontiers in Medicine doi 10.3389/fmed.2021.644154 5,725 views 5 citations Review Published on 26 Apr 2021 Current Pharmacogenetic Perspective on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Pharmacogenetics and Pharmacogenomics Lin Cheng Frontiers in Pharmacology doi 10.3389/fphar.2021.588063 34,101 views 41 citations Mini Review Published on 22 Feb 2021 Clinical Aspects of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis With Severe Ocular Complications in South Korea in Ophthalmology Mee Kum Kim Kyung Chul Yoon Sook Hyun Yoon Kyoung Yul Seo Frontiers in Medicine doi 10.3389/fmed.2021.640360 11,854 views 10 citations Case Report Published on 15 Aug 2025 Case Report: Hydronephrosis and nephrogenic adenoma secondary to Stevens-Johnson syndrome in Obstetric and Pediatric Pharmacology Chuan Wang Yidong Huang Frontiers in Pharmacology doi 10.3389/fphar.2025.1624432 1,840 views 2 citations
My brain will not stop scanning for problems. It feels like static or electrical pressure in my head. Even when I know the thought is irrational, it will not let go. This is why an effective natural therapy for OCD symptoms often focuses on calming glutamate, stabilizing NMDAR activity, strengthening inhibitory pathways such as GABA, and correcting methylation or copper-zinc imbalances
1184 Targeting mitochondria In autoimmune disorders, immune cells such as activated T and B cells often increase their mitochondrial OXPHOS to fulfill the substantial energy requirements for proliferation and immune responses
2023 The Journal of clinical investigation 133 (3) Features of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancer Shidan Wang, Ruichen Rong, Donghan M Yang, Junya Fujimoto, Justin A Bishop, Shirley Yan, Ling Cai, Carmen Behrens, Lynne D Berry, Clare Wilhelm, Dara Aisner, Lynette Sholl, Bruce E Johnson, David J Kwiatkowski, Ignacio I Wistuba, Paul A Bunn, John Minna, Guanghua Xiao, Mark G Kris, Yang Xie Jan 2023 The Journal of clinical investigation 133 (2) T-cell tolerant fraction as a predictor of immune-related adverse events Jared Ostmeyer, Jason Y Park, Mitchell S Von Itzstein, David Hsiehchen, Farjana Fattah, Mary Gwin, Rodrigo Catalan, Shaheen Khan, Prithvi Raj, Edward K Wakeland, Yang Xie , David E Gerber 2023 Journal for Immunotherapy of Cancer 11 (8) Association between immune-related adverse event timing and treatment outcomes David Hsiehchen, Abdul Rafeh Naqash, Magdalena Espinoza, Mitchell S Von Itzstein, Alessio Cortellini, Biagio Ricciuti, Dwight H Owen, Mehak Laharwal, Yukihiro Toi, Michael Burke, Yang Xie, David E Gerber Dec
